[Translation] A Phase III, multicenter, open-label, 12-week study evaluating the safety and tolerability of oral atogepant for migraine prevention in Chinese participants with chronic migraine
安全性和耐受性:在已完成研究3101-303-002(CM)的中国参与者中,评价atogepant 60 mg每日一次持续12周用于预防偏头痛的安全性和耐受性。
疗效:在中国CM参与者中,评价atogepant 60 mg每日一次持续给药12周用于预防偏头痛的疗效。
[Translation] Safety and Tolerability: To evaluate the safety and tolerability of atogepant 60 mg once daily for 12 weeks for the prevention of migraine in Chinese participants who have completed Study 3101-303-002 (CM).
Efficacy: To evaluate the efficacy of atogepant 60 mg once daily for 12 weeks for the prevention of migraine in Chinese participants with CM.